This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
biotechnology biotechs medical pharmaceuticals
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
biotechs medical pharmaceuticals
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
by Kinjel Shah
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
pharmaceuticals
Top Analyst Reports for Visa, Merck & Southern Company
by Mark Vickery
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
business-services construction finance pharmaceuticals utilities
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
biotechnology biotechs medical pharmaceuticals
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
biotechs medical pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
biotechnology biotechs medical pharmaceuticals